ZYUS Completes Acquisition of Revon Systems to Enhance Patient Data Collection Platform for Cannabinoid-Based Therapies

On August 6, 2019, VCBeat (WeChat ID: vcbeat) learned from foreign media reports that life sciences company ZYUS had officially announced the completion of its previously planned acquisition of Revon Systems, LLC (“Revon”), a healthcare technology company headquartered in Kentucky.

Revon has developed a platform connecting physicians and patients, enabling doctors to provide remote care and helping patients better manage their health. Dedicated to the development of digital therapeutics, Revon’s app currently offers simple, accessible, secure, and accurate information support, along with online guidance on proper care practices for patients with COPD and asthma.

Revon Systems’ research in respiratory diseases indicates that its technology is well-suited for any chronic condition characterized by worsening or acute symptoms.

ZYUS has long been dedicated to the global development and commercialization of innovative, patient-centric cannabinoid therapeutics and product candidates. During its planned future clinical studies and trials, ZYUS will leverage Revon Systems’ proprietary artificial intelligence technology platform as a digital therapeutic patient interface and real-time data collection platform, facilitated by its acquisition of the medical technology company Revon Systems.

Brent Zettl, President and CEO of ZYUS, stated, “We warmly welcome the Revon team to ZYUS and are pleased to leverage this proprietary technology platform in future clinical trials of our pain management candidate products. ZYUS will deepen patient engagement to better understand patient needs, develop innovative therapies, and accelerate the progress of clinical trials.”

ZYUS is a Canada-based life sciences company focused on the global development and commercialization of innovative cannabinoid-based therapies and product candidates. Through clinical research and intellectual property development, ZYUS aims to deliver high-quality oils, softgel capsules, topical creams, and other cannabinoid-based therapies and product candidates to patients worldwide. ZYUS’s vision is to elevate cannabinoids to a standard of medical care and expand their therapeutic potential to achieve transformative impacts on patients’ lives.

Revon is a medical technology company headquartered in Kentucky that has developed a data collection platform integrating mobile technologies and connected devices with healthcare services and treatments. The platform’s digital interface facilitates data collection to evaluate the performance of medications and other interventions across diverse patient populations. Revon’s technology platform provides pharmaceutical and medical device companies conducting clinical trials with intelligent enrollment services, real-world evidence collection, and tracking of patient-reported outcomes.

(Compiled by: Xu Wenjuan)